Mabapi le kankere / kalafo / liteko tsa bongaka / mafu / lisepa-bonolo-sarcoma / kalafo
Liteko tsa Meriana ea Kalafo bakeng sa Tissue Sarcoma e Bonolo
Liteko tsa bongaka ke lithuto tsa lipatlisiso tse amang batho. Liteko tsa bongaka lethathamong lena ke tsa kalafo e bonolo ea sarcoma. Liteko tsohle tse lenaneng li tšehelitsoe ke NCI.
Tlhahisoleseling ea mantlha ea NCI mabapi le liteko tsa bongaka e hlalosa mefuta le mekhahlelo ea liteko le hore na li etsoa joang. Liteko tsa bongaka li sheba mekhoa e mecha ea ho thibela, ho lemoha kapa ho phekola mafu. U kanna ua batla ho nahana ka ho nka karolo tekong ea bongaka. Bua le ngaka ea hau bakeng sa thuso ho etsa qeto ea hore na e nepahetse ho uena.
Erdafitinib ea ho Phekola Bakuli ba nang le lihlahala tse tiileng tse matla tse khutlisitsoeng kapa tse sa sebetseng, Non-Hodgkin Lymphoma, kapa Mathata a Histiocytic a nang le FGFR Mutations (Teko ea Phekolo ea Phekolo ea Phekolo ea Bana)
Karolo ea II ea bana ea liteko tsa MATCH e etsa liteko tsa hore na erdafitinib e sebetsa joang ho phekola bakuli ba nang le lihlahala tse tiileng, e seng Hodgkin lymphoma, kapa mathata a histiocytic a hasaneng libakeng tse ling 'meleng mme a khutlile kapa a sa arabele kalafo ka liphetoho tsa FGFR. Erdafitinib e ka emisa kholo ea lisele tsa mofetše ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 107
Tazemetostat ea ho Phekola Bakuli ba nang le lihlahala tse tiileng tse matla tse khutlisitsoeng hape tse sa sebetseng hantle, Non-Hodgkin Lymphoma, kapa Mathata a Histiocytic a nang le EZH2, SMARCB1, kapa SMARCA4 Gene Mutations (Teko ea Phekolo ea Phekolo ea Bana)
Karolo ena ea II ea bana ea liteko tsa MATCH e etsa liteko tsa hore na tazemetostat e sebetsa joang ho phekola bakuli ba nang le lihlahala tse tiileng, non-hodgkin lymphoma, kapa mathata a histiocytic a hasaneng libakeng tse ling 'meleng mme a khutlile kapa a sa arabele kalafo mme a na le EZH2, SMARCB1 , kapa liphetoho tsa lefutso tsa SMARCA4. Tazemetostat e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 109
PI3K / mTOR Inhibitor LY3023414 ho Phekola bakuli ba nang le lihlahala tse tiileng tse matla tse khutlisitsoeng kapa tse sa sebetseng, Non-Hodgkin Lymphoma, kapa Mathata a Histiocytic a nang le TSC kapa PI3K / MTOR Mutations (Teko ea Phekolo ea Phekolo ea Phekolo ea Bana)
Karolo ena ea II ea bana ea liteko tsa MATCH e etsa liteko tsa hore na PI3K / mTOR inhibitor LY3023414 e sebetsa joang ho phekola bakuli ba nang le lihlahala tse tiileng, e seng Hodgkin lymphoma, kapa mathata a histiocytic a nang le liphetoho tsa TSC kapa PI3K / MTOR tse hasaneng libakeng tse ling 'meleng (metastatic) le ba khutlile (ba ipheta) kapa ha ba arabele kalafo (refractory). PI3K / mTOR inhibitor LY3023414 e ka emisa kholo ea lisele tsa mofetše ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 107
Palbociclib ea ho Phekola Bakuli ba nang le lihlahala tse matla tse khutlisitsoeng kapa tse sa sebetseng tsa Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, kapa Mathata a Histiocytic a Sebetsang Liphetoho ho Cell Cycle Genes (Teko ea Phekolo ea Phekolo ea Phekolo ea Bana)
Karolo ena ea II ea bana ea liteko tsa MATCH e etsa liteko tsa hore na palbociclib e sebetsa joang ho phekola bakuli ba nang le lihlahala tse tiileng tsa Rb, e seng Hodgkin lymphoma, kapa mathata a histiocytic a etsang liphetoho (liphetoho) liphatseng tsa lefutso tsa sele tse hasaneng libakeng tse ling 'meleng' me li fihlile khutlela morao kapa ho se arabele kalafo. Palbociclib e ka emisa kholo ea lisele tsa mofetše ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 97
Larotrectinib ea ho Phekola Bakuli ba nang le lihlahala tse tiileng tse matla tse khutlisitsoeng kapa tse sa sebetseng, Non-Hodgkin Lymphoma, kapa Mathata a Histiocytic a nang le NTRK Fusions (Teko ea Phekolo ea Phekolo ea Phekolo ea Bana)
Karolo ea II ea bana ea liteko tsa MATCH e etsa liteko tsa hore na larotrectinib e sebetsa joang ho phekola bakuli ba nang le lihlahala tse tiileng, e seng Hodgkin lymphoma, kapa mathata a histiocytic a nang le litlamorao tsa NTRK tse hasaneng libakeng tse ling 'meleng mme li khutlile kapa ha li arabele kalafo. Larotrectinib e ka emisa kholo ea lisele tsa mofetše ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 109
Cabozantinib-S-Malate ho Phekola Bakuli ba Bacha ba nang le Recurrent, Refractory, kapa Sarcomas e sa tsoa fumanoa, Wilms Tumor, kapa lihlahala tse ling tse sa tloaelehang.
Karolo ea liteko tsa mohato ona oa bobeli e ithuta kamoo cabozantinib-s-malate e sebetsang hantle ho phekola bakuli ba banyane ba nang le sarcomas, hlahala ea Wilms, kapa lihlahala tse ling tse sa tloaelehang tse khutlileng, ha li arabele kalafo, kapa li sa tsoa fumanoa. Cabozantinib-s-malate e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea hlahala le kholo ea sejana sa mali.
Sebaka: libaka tse 137
Olaparib ea ho Phekola Bakuli ba nang le lihlahala tse tiileng tse matla tse khutlisitsoeng hape tse sa sebetseng, Non-Hodgkin Lymphoma, kapa Mathata a Histiocytic a nang le liphoso tsa Ts'enyo ea Ts'enyo ea DNA (Teko ea Phekolo ea Phekolo ea Bana)
Karolo ena ea II ea bana ea liteko tsa MATCH e etsa lipatlisiso hore na olaparib e sebetsa joang ho phekola bakuli ba nang le lihlahala tse tiileng, e seng Hodgkin lymphoma, kapa mathata a histiocytic a nang le liphoso tsa liphatsa tsa lefutso tsa deoxyribonucleic acid (DNA) tse hasaneng libakeng tse ling 'meleng (tse tsoetseng pele) le ke khutlile (ke khutlile hape) kapa ha ke arabele kalafo (refractory). Olaparib e ka emisa kholo ea lisele tsa hlahala ka ho thibela li-enzyme tse ling tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 105
Vemurafenib ea ho Phekola Bakuli ba nang le lihlahala tse tiileng tse matla tse khutlisitsoeng kapa tse sa sebetseng, Non-Hodgkin Lymphoma, kapa Mathata a Histiocytic a nang le liphetoho tsa BRAF V600 (Teko ea Phekolo ea Phekolo ea Bana)
Karolo ena ea II ea bana ea liteko tsa MATCH e etsa liteko tsa hore na vemurafenib e sebetsa joang ho phekola bakuli ba nang le lihlahala tse tiileng, e seng Hodgkin lymphoma, kapa mathata a histiocytic a nang le liphetoho tsa BRAF V600 tse hasaneng libakeng tse ling 'meleng mme li khutlile kapa ha li arabele kalafo. Vemurafenib e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 106
Atezolizumab ea ho Phekola Bakuli ba nang le karolo e ncha e fumanoeng le Metastatic Alveolar Soft Part Sarcoma e ke keng ea tlosoa ke ho buoa
Karolo ena ea liteko tsa mohato oa II e ithuta hore na atezolizumab e sebetsa hantle hakae ho phekola bakuli ba nang le alveolar soft part sarcoma e sa kang ea phekoloa, e namme ho tloha moo e qalileng teng ho ea libakeng tse ling 'meleng mme e ke ke ea tlosoa ka ho buuoa. Immunotherapy e nang le lithibela-mafu tse monoclonal, joalo ka atezolizumab, e ka thusa boits'ireletso ba mmele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana.
Sebaka: libaka tse 39
Nivolumab le Ipilimumab ha ba Phekola Bakuli ba nang le HIV ba amanang le ho khutla hape kapa ba nang le bothata ba Hodgkin Lymphoma kapa lihlahala tse tiileng tse nang le metastatic kapa tse ke keng tsa tlosoa ke ho buoa
Karolo ena ea liteko tsa karolo ea pele e hlahloba litla-morao le tekanyo e ntle ea nivolumab ha e fanoa ka ipilimumab ho phekola bakuli ba nang le vaerase ea ho itšireletsa mafung (HIV) e amanang le Hodgkin lymphoma ea khale e khutlileng kamora nako ea ntlafatso kapa e sa arabeleng kalafo, kapa lihlahala tse tiileng tse e hasane libakeng tse ling 'meleng kapa e ke ke ea tlosoa ka ho buuoa. Immunotherapy e nang le lithibela-mafu tse monoclonal, tse kang ipilimumab le nivolumab, e ka thusa sesole sa 'mele ho hlasela mofetše, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ipilimumab ke antibody e sebetsang khahlanong le molek'hule e bitsoang cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 e laola karolo ea sesole sa hau sa 'mele ka ho e koala. Nivolumab ke mofuta oa antibody e ikhethileng bakeng sa lefu la motho le entsoeng 1 (PD-1), protheine e ikarabellang bakeng sa ho senya lisele tsa 'mele. Ho fana ka ipilimumab ka nivolumab ho ka sebetsa betere ho phekoleng bakuli ba nang le HIV ba amanang le Hodgkin lymphoma kapa lihlahala tse tiileng ha li bapisoa le ipilimumab le nivolumab feela.
Sebaka: libaka tse 28
MDM2 Inhibitor AMG-232 le Therapy ea radiation ho phekola bakuli ba nang le dinama tse bonolo tsa Sarcoma
Karolo ena ea liteko tsa Ib e ithuta ka litla-morao tsa MDM2 inhibitor AMG-232 le kalafo ea radiation ho phekola bakuli ba nang le lisele tse bonolo tsa sarcoma. MDM2 inhibitor AMG-232 e ka emisa kholo ea lisele tsa mofetše ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele. Ho fana ka MDM2 inhibitor AMG-232 le kalafo ea radiation pele ho ts'ebetso e ka etsa hore hlahala e be nyane mme ea fokotsa palo ea lisele tse tloaelehileng tse hlokang ho tlosoa.
Sebaka: libaka tse 27
Nivolumab e nang le Ipilimumab kapa e se na eona ho phekola bakuli ba banyenyane ba nang le lihlahala tse tiileng tse iphetang kapa tse sa tsitsang kapa Sarcomas
Teko ena ea karolo ea II / II e ithuta litla-morao le tekanyo e ntle ea nivolumab ha e fanoa ka kapa ntle le ipilimumab ho bona hore na ba sebetsa hantle hakae ho phekola bakuli ba banyane ka lihlahala tse tiileng kapa sarcomas tse khutlileng (tse iphetang) kapa tse sa arabeleng kalafo ( tshekatsheko). Immunotherapy e nang le li-antibodies tsa monoclonal, joalo ka nivolumab le ipilimumab, e ka thusa sesole sa 'mele ho hlasela mofets'e, mme e ka sitisa bokhoni ba lisele tsa hlahala ho hola le ho hasana. Ha ho e-so tsejoe hore na nivolumab e sebetsa betere e le 'ngoe kapa e na le ipilimumab ho phekola bakuli ba nang le lihlahala tse matla tse iphetang kapa tse hanyetsang.
Sebaka: libaka tse 24
Selinexor ho Advanced Liposarcoma
Ena ke tlhaiso-leseling e mengata, e nang le mahlo a mabeli, e laoloang habobebe, e laoloang ke placebo, Phase 2-3 ea bakuli ba fumanoeng ba e-na le dedifferentiated liposarcoma e tsoetseng pele. Hoo e ka bang bakuli ba 279 ka kakaretso ba tla hlophisoa ka mokhoa oa ho ithuta kalafo (selinexor kapa placebo).
Sebaka: libaka tse 21
(VOYAGER) Boithuto ba Avapritinib vs Regorafenib ho bakuli ba nang le GIST ea Metastatic e ke keng ea qojoa sebakeng sa heno.
Ena ke phuputso e bulehileng, e hlophisitsoeng, ea Phase 3 ho bakuli ba nang le GIST (advanced GIST) ea avapritinib (e tsejoang hape e le BLU-285) khahlanong le regorafenib ho bakuli ba neng ba kile ba phekoloa ka imatinib le 1 kapa 2 li-TKIs tse ling.
Sebaka: libaka tse 14
Phuputso ea Mokhahlelo oa 1 oa EZH2 Inhibitor Tazemetostat ho Bafo ba Bana ba nang le lihlahala tsa INI1-Negative kapa Synovial Sarcoma.
Ena ke Phase I, label e bulehileng, ho nyoloha ha lethal dose le thuto ea katoloso ea tekanyetso ka tekanyetso ea molomo ea BID ea tazemetostat. Lihlooho li tla hlahlojoa hore na lia tšoaneleha nakong ea matsatsi a 14 ho tloha tekanyong ea pele ea tazemetostat. Potoloho ea kalafo e tla nka matsatsi a 28. Tekolo ea likarabo e tla hlahlojoa kamora libeke tse 8 tsa kalafo mme kamora beke tse ling le tse ling tsa 8 ha ba ntse ba ithuta. Boithuto bo na le likarolo tse peli: Keketso ea Dose le Katoloso ea Dose. Ho phahama ha lethopo bakeng sa lihlooho tse nang le malignancies a latelang a khutlileng hape a sa sebetseng: - Lihlahala tsa Rhabdoid: - Hlahala e matla ea teratoid rhabdoid (ATRT) - Malignant rhabdoid tumor (MRT) - Rhabdoid tumor ea liphio (RTK) - Lihlahala tse khethiloeng tse nang le likarolo tsa rhabdoid - lihlahala tsa INI1-tse mpe :
Sebaka: libaka tse 14
Adavosertib le Irinotecan Hydrochloride ho Phekola Bakuli ba Bacha ba nang le lihlahala tse tiileng tse khutlisitsoeng kapa tse sa sebetseng.
Karolo ea teko ea I / II e ithuta ka litla-morao le lethal dose ea adavosertib le irinotecan hydrochloride ho phekola bakuli ba banyane ka lihlahala tse tiileng tse khutlileng (tse khutlileng hape) kapa tse sa kang tsa arabela kalafo e tloaelehileng (e hanyetsang). Adavosertib le irinotecan hydrochloride li ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 22
Teko ea Phase III ea Anlotinib ho Metastatic kapa Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma le Synovial Sarcoma
Phuputso ena e lekola polokeho le katleho ea AL3818 (anlotinib) hydrochloride kalafong ea metastatic kapa advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), le synovial sarcoma (SS). Barupeluoa bohle ba nang le ASPS ba tla amohela AL-Al1818. Ho bankakarolo ba nang le LMS kapa SS, AL3818 e tla bapisoa le IV dacarbazine. Karolo ea bobeli borarong ea bankakarolo e tla fumana AL3818, karolo ea boraro ea bankakarolo e tla amohela IV dacarbazine.
Sebaka: libaka tse 14
Nab-Paclitaxel le Gemcitabine Hydrochloride ea ho Phekola Bacha kapa Bacha ba baholo ba nang le Osteosarcoma e iphetang kapa e sa sebetseng, Ewing Sarcoma, Rhabdomyosarcoma, kapa Soft Tissue Sarcoma
Karolo ea liteko tsa mohato ona oa bobeli e ithuta hore na nab-paclitaxel le gemcitabine hydrochloride li sebetsa joang ho phekoleng bacha kapa batho ba baholo ba nang le lefu la osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, kapa 'mele o bonolo o khutlileng kapa o sa arabeleng kalafo. Lithethefatsi tse sebelisoang ho chemotherapy, joalo ka nab-paclitaxel le gemcitabine hydrochloride, li sebetsa ka litsela tse fapaneng ho emisa kholo ea lisele tsa hlahala, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li emisa ho hasana.
Sebaka: libaka tse 18
Olaparib le Temozolomide ho Phekola Bakuli ba nang le Uterine Leiomyosarcoma e tsoetseng pele, e sa tsitsang kapa e sa bonahaleng.
Karolo ea II ea liteko tsa liteko tsa olaparib le temozolomide ho phekola bakuli ba uterine leiomyosarcoma (LMS) e hasaneng libakeng tse ling 'meleng (e tsoetseng pele kapa metastatic) kapa e ke keng ea tlosoa ka ho buuoa (e ke keng ea qojoa). Olaparib e ka emisa kholo ea lisele tsa hlahala ka ho thibela li-enzyme tse ling tse hlokahalang bakeng sa kholo ea lisele. Lithethefatsi tse sebelisoang ho chemotherapy, joalo ka temozolomide, li sebetsa ka litsela tse fapaneng ho emisa kholo ea lisele tsa hlahala, ekaba ka ho bolaea lisele, ka ho li emisa ho arohana, kapa ka ho li emisa ho hasana. Ho fana ka olaparib le temozolomide ho ka sebetsa hantle ho feta ho fana ka sethethefatsi se le seng ho phekola bakuli ba LMS.
Sebaka: libaka tse 12
Ts'ireletso, mamello le thuto ea PK ea DCC-2618 ho bakuli ba nang le malignancies a tsoetseng pele
Ena ke thuto ea phase 1, open-lab, first-in-human (FIH) ea tekanyetso ea litekanyetso e etselitsoeng ho lekola polokeho, mamello, pharmacokinetics (PK), pharmacodynamics (PD) le ts'ebetso ea pele ea antitumor ea DCC-2618, e tsamaisoang ka molomo (PO), ho bakuli ba baholo ba nang le malignancies a tsoetseng pele. Boithuto bo na le likarolo tsa 2, mohato oa keketseho ea litekanyetso le mohato oa katoloso.
Sebaka: libaka tse 12
Nelfinavir Mesylate ea ho Phekola Bakuli ba nang le Kaposi Sarcoma
Teko ena ea karolo ea II ea sefofane e ithuta hore na nelfinavir mesylate e sebetsa joang ho phekola bakuli ba nang le Kaposi sarcoma. Nelfinavir mesylate e ka emisa kholo ea lisele tsa hlahala ka ho thibela tse ling tsa li-enzyme tse hlokahalang bakeng sa kholo ea lisele.
Sebaka: libaka tse 11
sEphB4-HSA ho Phekola Bakuli ba nang le Kaposi Sarcoma
Karolo ea II ea liteko tsa liteko tsa recombinant EphB4-HSA fusion protein (sEphB4-HSA) ho phekola bakuli ba nang le Kaposi sarcoma. Protheine e kopantseng ea recombinant EphB4-HSA e ka thibela kholo ea methapo ea mali e fanang ka mali ho mofets'e, hape e ka thibela lisele tsa mofetše ho hola.
Sebaka: libaka tse 10
Phase II, Study Multicenter ea EZH2 Inhibitor Tazemetostat ho Batho ba baholo ba nang le li-Tumors tsa INI1-Negative kapa Synovial Sarcoma e Khutlileng
Ena ke Phase II, multicenter, open-label, letsoho le le leng, boithuto ba mekhahlelo e 'meli ea tazemetostat 800 mg BID e tsamaisoang ka molomo matsatsing a tsoelang pele a matsatsi a 28. Ho hlahlojoa ha litaba ho fumana hore na thuto ea tšoaneleha ho tla etsoa matsatsing a 21 ho tloha tekanyong ea pele ea tazemetostat. Lihlooho tse tšoanelehang li tla ngolisoa ho e 'ngoe ea lino tse tahang tse hlano tse ipapisitseng le mofuta oa hlahala: - Cohort 1 (E koetsoe ho ngolisoa): MRT, RTK, ATRT, kapa lihlahala tse khethiloeng tse nang le likarolo tsa rhabdoid, ho kenyeletsoa le cell caroma e nyane ea mofuta oa ovary hypercalcemic [SCCOHT], hape e tsejoang e le hlahala e kotsi ea "ovary" ea "ovary [MRTO] - Cohort 2 (E koetsoe bakeng sa ngoliso): Sarcoma e khutlisitsoeng kapa e sa sebetseng ea synovial sarcoma le SS18-SSX rearrangement - Cohort 3 (E koetsoe ho ngolisoa): Lihlahala tse ling tsa INI1 tse mpe kapa hlahala efe kapa efe e tiileng e nang le EZH2 phaello ea ts'ebetso (GOF), ho kenyelletsa:
Sebaka: libaka tse 12
SARC024: Protocol ea Blanket ea ho Ithuta Oral Regorafenib ho bakuli ba nang le mefuta e khethiloeng ea Sarcoma
Le ha regorafenib e ile ea amoheloa hore e sebelisoe ho bakuli ba neng ba na le GIST e tsoelang pele leha e le imatinib le / kapa sunitinib motheong oa data ea phase II le phase III, ha e so ka e hlahlojoa ka mokhoa o hlophisehileng ho bakuli ba nang le mefuta e meng ea sarcoma. Ha ho fanoa ka tšebetso ea sorafenib, sunitinib le pazopanib ka lisarcomas tse bonolo, le bopaki ba ts'ebetso ea sorafenib ho osteogenic sarcoma mme mohlomong le Ewing / Ewing-like sarcoma, ho na le mohlala oa ho hlahloba li-SMOKI (li-molek'hule tse nyane tsa molomo oa kinase inhibitors) joalo ka regorafenib ho sarcomas Ntle le GIST. Ho boetse ho ananeloa hore li-SMOKI (molek'hule tse nyane tsa molomo kinase inhibitors) joalo ka regorafenib, sorafenib, pazopanib, le sunitinib li na le likarolo tse kopaneng tsa kinase tse thibetsoeng ka nako e le ngoe. Le ha e sa lekana,
Sebaka: libaka tse 10
Polokeho, mamello le Pharmacokinetics ea anti-PD-1 Monoclonal Antibody ho bafo ba nang le malignancies a tsoetseng pele.
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of Toripalimab, 2) evaluate antitumor activity of Toripalimab; 3) determine the immunogenicity of Toripalimab; 4) evaluate overall survival. The exploratory objectives are to: 1) evaluate biomarkers that may correlate with activity of Toripalimab, 2) evaluate pharmacodynamic effects of Toripalimab on its target receptor, programmed cell death 1 (PD-1), as well as effects on the immune system. 3) evaluate the utility of PD-L1 & additional exploratory markers as biomarkers that could aid in selection of appropriate subjects for TAB001 therapy, and 4) identification of additional biomarkers correlating with response to treatment with TAB001.
Sebaka: libaka tse 9
